abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

ADCYAP1R1
Back
Total number of drugs
7
Phase II and later clinical stages
14.3%
Involving companies
8
Main therapeutic areas
Nervous System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
Anti-CGRPR/PAC1R bispecific antibody(Amgen)Anti-CGRPR/PAC1R bispecific antibody(Amgen)Bispecific antibodyNervous System DiseasesPituitary adenylate cyclase-activating polypeptide type I receptor antagonists Calcitonin gene-related peptide type 1 receptor antagonistsAmgen, Inc.Amgen, Inc.PreclinicalAnti-CGRPR/PAC1R bispecific antibody(Amgen)
detail  >
BAY 2686013BAY 2686013Small molecule drugNervous System DiseasesPituitary adenylate cyclase-activating polypeptide type I receptor antagonistsBayer AGBayer AGPreclinicalBAY 2686013
detail  >
MT-001 (Mentari)MT-001 (Mentari)Monoclonal antibodyNervous System DiseasesPituitary adenylate cyclase-activating polypeptide type I receptor antagonistsParagon Therapeutics, Inc.Mentari Therapeutics, Inc.PreclinicalMT-001 (Mentari)
detail  >
MT-002 (Mentari)MT-002 (Mentari)Bispecific antibodyNervous System DiseasesPituitary adenylate cyclase-activating polypeptide type I receptor antagonists Calcitonin gene-related peptide antagonistsParagon Therapeutics, Inc.Mentari Therapeutics, Inc.PreclinicalMT-002 (Mentari)
detail  >
SPAM1SPAM1Small molecule drugPituitary adenylate cyclase-activating polypeptide type I receptor modulatorsJinan UniversityJinan UniversityPreclinicalPreclinicalSPAM1
detail  >
MAXCAPsMAXCAPsFusion proteinDigestive System DisordersPituitary adenylate cyclase-activating polypeptide type I receptor agonistsBausch Health Cos., Inc.University of California, Los AngelesSalix Pharmaceuticals, Inc.PreclinicalMAXCAPs
detail  >
ZelminemabZelminemabMonoclonal antibodyNervous System DiseasesPituitary adenylate cyclase-activating polypeptide type I receptor antagonistsAmgen, Inc.Phase 2Zelminemab
detail  >
Total 7 data
1